British pharmaceutical company GSK is turning to patient data gathered from the 88 million residents of the Greater Bay Area’s 11 cities to speed up drug development in vaccines and cancer care, as officials push for closer cross-border medical cooperation. GSK Hong Kong and Macau general manager Nicholas Teo said patient data was very important because it could form “supplementary evidence” to support regulatory filings and potential label expansions, and also help to “discover benefits other...